Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accumulated Expenses for 16 consecutive years, with $15.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 132.38% to $15.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 million, a 132.38% increase, with the full-year FY2025 number at $15.9 million, up 132.38% from a year prior.
  • Accumulated Expenses was $15.9 million for Q4 2025 at Anika Therapeutics, up from $14.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $18.7 million in Q3 2024 to a low of $5.7 million in Q1 2021.
  • A 5-year average of $11.8 million and a median of $11.1 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 164.35% in 2021, then plummeted 67.75% in 2025.
  • Anika Therapeutics' Accumulated Expenses stood at $9.5 million in 2021, then rose by 18.69% to $11.3 million in 2022, then grew by 24.44% to $14.1 million in 2023, then crashed by 51.46% to $6.8 million in 2024, then surged by 132.38% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Accumulated Expenses are $15.9 million (Q4 2025), $14.4 million (Q3 2025), and $6.0 million (Q2 2025).